Project Grant R01DK145193
Award Date 8/10/26
Completion Date 5/31/31
Dollars Obligated $820K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $295,649 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate adipocyte FGF1 signaling in systemic metabolism. The research examines fibroblast growth factor 1 (FGF1) as a potential lipid-lowering therapeutic target for hyperlipidemia and related metabolic disorders. Preliminary studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $1.933 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a clinical trial examining semaglutide microdosing in people living with HIV. The REINFORCE Trial investigates whether low-dose (0.5 milligram weekly) semaglutide maintenance therapy sustains weight loss and cardiometabolic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas at San Antonio $221,252 on September 12, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a drug delivery system that modulates adipose tissue function. The project creates a locally injected adipose tissue nano-reservoir for continuous delivery of forskolin, a cyclic adenosine monophosphate activator that stimulates fat...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $1,557,623 to The University of Texas Health Science Center at San Antonio on September 10, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate glucagon-mediated glycemic effects in humans with and without rerouted gastrointestinal anatomy following bariatric surgery. The research examines how glucagon regulates blood glucose levels in patients who have...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $835,245 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to evaluate evidence-based strategies for preventing weight regain after discontinuation of high-dose glucagon-like peptide-1 (GLP-1) agonist therapy in adults with obesity history but...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Chicago $123,000 on June 16, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize adipocyte heterogeneity and response to metabolic stress. The funded research uses single-nucleus RNA sequencing and a humanized mouse model to investigate how diverse stimuli influence white adipocyte development and specification, with emphasis on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Health Science Center at San Antonio $707,781 on May 22, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify cell type-specific insulin-responsive quantitative trait loci in human skeletal muscle relevant to type 2 diabetes pathogenesis. The research uses single-nuclei RNA sequencing and assay for transposase-accessible chromatin with...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Texas Woman's University $133,175 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of DHRS9 in diet-induced obesity and diabetes. The research project will define how DHRS9 modulates insulin sensitivity under high-fat diet conditions across sexes and determine whether retinoid or specialized pro-resolving mediator (SPM)...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $1.634 million on September 17, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to decode the neural mechanisms underlying bariatric surgery outcomes through activity and transcriptional analysis of melanocortin neurons. The recipient will employ electrophysiological techniques to study alterations in neuronal...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $694,250 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to explore a novel pathway for ApoB mRNA degradation in regulating VLDL secretion and steatotic liver disease. The recipient will conduct basic biomedical research identifying mechanisms by which the HELZ2 gene regulates hepatic lipid secretion...